Display Settings:

Format

Send to:

Choose Destination
    Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10526-31.

    Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury.

    Source

    The Kenneth S. Warren Laboratories, 765 Old Saw Mill River Road, Tarrytown, NY 10591, USA. mbrines@kswl.org

    Abstract

    Erythropoietin (EPO), recognized for its central role in erythropoiesis, also mediates neuroprotection when the recombinant form (r-Hu-EPO) is directly injected into ischemic rodent brain. We observed abundant expression of the EPO receptor at brain capillaries, which could provide a route for circulating EPO to enter the brain. In confirmation of this hypothesis, systemic administration of r-Hu-EPO before or up to 6 h after focal brain ischemia reduced injury by approximately 50-75%. R-Hu-EPO also ameliorates the extent of concussive brain injury, the immune damage in experimental autoimmune encephalomyelitis, and the toxicity of kainate. Given r-Hu-EPO's excellent safety profile, clinical trials evaluating systemically administered r-Hu-EPO as a general neuroprotective treatment are warranted.

    PMID:
    10984541
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC27058
    Free PMC Article

    Images from this publication.See all images (6) Free text

    Figure 2
    Figure 4
    Figure 6
    Figure 1
    Figure 3
    Figure 5

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk